NDA for ADHD Med That Is Dosed at Night Resubmitted to FDA
Monthly Prescribing Reference
The Food and Drug Administration (FDA) has accepted a resubmitted New Drug Application (NDA) for the investigational treatment HLD200 (Ironshore Pharmaceuticals) for attention deficit hyperactivity disorder (ADHD). HLD200, a delayed-release and ...
Ironshore Pharmaceuticals Announces PDUFA Date of August 8, 2018 for HLD200